Summary & Overview
HCPCS Level II J9280: Injection, Mitomycin 5 mg
HCPCS Level II code J9280 denotes the administration of mitomycin, 5 mg, an antineoplastic agent used in oncology care. This national billing descriptor captures the drug component for a discrete 5 mg dose and is used across outpatient infusion centers and oncology clinics where chemotherapy agents are administered. Accurate coding of drug J-codes like J9280 matters for claims processing, payment integrity, and clinical documentation linking therapy to diagnosis and treatment plans.
Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what the code represents, typical sites of service, common modifiers and billing considerations (listed separately), and the clinical context for mitomycin administration. The publication outlines benchmarks and policy-relevant points affecting reimbursement and prior authorization processes, as well as operational considerations for outpatient infusion workflows.
This summary equips billing managers, revenue cycle staff, and clinical leadership with a clear understanding of the code’s purpose, payer landscape, and topics to review when reconciling oncology drug claims. Data not available in the input is noted where specific payer policy details, associated taxonomies, ICD-10 pairings, and related codes would normally be provided.
Billing Code Overview
HCPCS Level II code J9280 represents an injection of mitomycin, 5 mg. This code describes the administration of the antineoplastic agent mitomycin in a 5 mg dose.
Service type: Drug injection/administration
Typical site of service: Outpatient infusion or oncology clinic
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a superficial bladder tumor or intravesical recurrence of non–muscle-invasive bladder cancer referred for intravesical chemotherapy using mitomycin C. The patient presents to an outpatient urology clinic or ambulatory surgery center for a scheduled instillation or intravesical injection of J9280 (mitomycin, 5 mg). Pre-procedure workflow includes review of recent cystoscopy findings, urine cytology, and confirmation of no active urinary tract infection. The nurse verifies allergies and obtains informed consent. In the procedure room, the patient is placed in lithotomy position; topical or local urethral anesthesia may be applied. Cystoscopy is performed when indicated, tumor sites are visualized and biopsied if required. Instillation of mitomycin (reconstituted to the prescribed concentration) is delivered intravesically via catheter; dwell time is documented. Post-procedure monitoring occurs for short-term adverse effects (irritative voiding, hematuria). The visit is coded with J9280 for the drug administration; associated facility and procedure codes are billed separately according to the services performed and modifiers applied as appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug or biological amount discarded/unused |